AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial - AbbVie (NYSE:ABBV)

AbbVie's Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial - AbbVie (NYSE:ABBV)

AbbVie Inc (NYSE:ABBV) on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month. The study met the primary endpoint of treatment discontinuation due to adverse events (AEs), demonstrating th…

AbbVie’s Phase III trial of atogepant for migraine meets primary goal

AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its primary endpoint.The post AbbVie’s Phase III trial of atogepant for migraine meets primary goal appeared first on Clinical Trials Arena.

CGRP Therapy Atogepant Outperforms Topiramate in Head-to-Head TEMPLE Trial

Atogepant outperforms topiramate in migraine prevention, showcasing superior efficacy and safety in the phase 3 TEMPLE trial results.